Daclizumab for the treatment of multiple sclerosis. (October 2017)

• Record Type: Journal Article
• Authors: Papadopoulou, Athina; Derfuss, Tobias; Sprenger, Till
• Is Part Of: Neurodegenerative disease management. Volume 7:Number 5(2017)
• Page Start: 279
• Page End: 297
• Publication Date: 2017-10
• Subjects: anti-CD25 -- CD56bright natural killer cells DAC HYP -- daclizumab-β -- interleukin-2 -- monoclonal antibody; Nervous system -- Degeneration -- Periodicals; 616.8
• DOI: 10.2217/nmt-2017-0023
• Languages: English
• ISSNs: 1758-2024

Abstract

Daclizumab is a monoclonal antibody that targets the α-chain of the IL-2 receptor. Results of Phase II and III clinical trials showed efficacy of daclizumab in relapsing-remitting multiple sclerosis, with reduction of annualized relapse rate by 50–54% versus placebo and 45% versus intramuscular IFN-β-1a. Certain aspects of the immunomodulatory mode of action of daclizumab were only discovered during its clinical development, such as the expansion of a subpopulation of natural killer cells. In this article, we outline the putative mechanisms of action and the key clinical data on daclizumab, with a focus on the efficacy and safety profile. We also evaluate its potential role in future treatment algorithms of multiple sclerosis.